CVRx Inc
NASDAQ:CVRX
CVRx Inc
Revenue
CVRx Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CVRx Inc
NASDAQ:CVRX
|
Revenue
$51.3m
|
CAGR 3-Years
58%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$20.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$16.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$22.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$42B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$8.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
CVRx Inc
Revenue Breakdown
Breakdown by Geography
CVRx Inc
|
Total Revenue:
51.3m
USD
|
|
United States:
47.2m
USD
|
|
Germany:
3.5m
USD
|
|
Represents The Information Pertaining To Othe...:
665k
USD
|
Breakdown by Segments
CVRx Inc
CVRx Inc
Glance View
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
See Also
What is CVRx Inc's Revenue?
Revenue
51.3m
USD
Based on the financial report for Dec 31, 2024, CVRx Inc's Revenue amounts to 51.3m USD.
What is CVRx Inc's Revenue growth rate?
Revenue CAGR 5Y
52%
Over the last year, the Revenue growth was 31%. The average annual Revenue growth rates for CVRx Inc have been 58% over the past three years , 52% over the past five years .
You don't have any saved screeners yet